Literature DB >> 32135565

Plasma Protein Signatures of a Murine Venous Thrombosis Model and Slc44a2 Knockout Mice Using Quantitative-Targeted Proteomics.

Julia Tilburg1, Sarah A Michaud2, Chrissta X Maracle1, Henri H Versteeg1, Christoph H Borchers2,3,4, Bart J M van Vlijmen1, Yassene Mohammed2,5,6.   

Abstract

The plasma compartment of the blood holds important information on the risk to develop cardiovascular diseases such as venous thrombosis (VT). Mass spectrometry-based targeted proteomics with internal standards quantifies proteins in multiplex allowing generation of signatures associated with a disease or a condition. Here, to demonstrate the method, we investigate the plasma protein signatures in mice following the onset of VT, which was induced by RNA interference targeting the natural anticoagulants antithrombin and protein C. We then study mice lacking Slc44a2, which was recently characterized as a VT-susceptibility gene in human genome-wide association studies. We use a recently developed panel of 375 multiplexed mouse protein assays measured by mass spectrometry. A strong plasma protein siganture was observed when VT was induced. Discriminators included acute phase response proteins, and proteins related to erythrocyte function. In mice lacking Slc44a2, protein signature was primarily overruled by the difference between sexes and not by the absent gene. Upon separate analyses for males and females, we were able to establish a signature for Slc44a2 deficiency, in which glycosylation-dependent cell adhesion molecule-1 and thrombospondin-1 were shared by both sexes. The minimal impact of Slc44a2 deficiency on the measured plasma proteins suggests that the main effect of Slc44a2 on VT does not lay ultimately in the plasma compartment. This suggests further investigation into the role of this VT-susceptibility gene should perhaps also question the possible involvement in cellular mechanisms. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32135565     DOI: 10.1055/s-0040-1702229

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  An Update on MRMAssayDB: A Comprehensive Resource for Targeted Proteomics Assays in the Community.

Authors:  Pallab Bhowmick; Simon Roome; Christoph H Borchers; David R Goodlett; Yassene Mohammed
Journal:  J Proteome Res       Date:  2021-03-08       Impact factor: 4.466

2.  Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.

Authors:  Yassene Mohammed; Carolina E Touw; Banne Nemeth; Raymond A van Adrichem; Christoph H Borchers; Frits R Rosendaal; Bart J van Vlijmen; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2022-01-06       Impact factor: 16.036

3.  Proteotyping of knockout mouse strains reveals sex- and strain-specific signatures in blood plasma.

Authors:  Yassene Mohammed; Sarah A Michaud; Helena Pětrošová; Juncong Yang; Milan Ganguly; David Schibli; Ann M Flenniken; Lauryl M J Nutter; Hibret A Adissu; K C Kent Lloyd; Colin McKerlie; Christoph H Borchers
Journal:  NPJ Syst Biol Appl       Date:  2021-05-28

4.  SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis.

Authors:  Julia Tilburg; Daniëlle M Coenen; Gaia Zirka; Sophie Dólleman; Annemarie M van Oeveren-Rietdijk; Mieke F A Karel; Hetty C de Boer; Judith M E M Cosemans; Henri H Versteeg; Pierre E Morange; Bart J M van Vlijmen; Chrissta X Maracle; Grace M Thomas
Journal:  J Thromb Haemost       Date:  2020-05-15       Impact factor: 5.824

5.  The choline transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial function.

Authors:  J Allen Bennett; Michael A Mastrangelo; Sara K Ture; Charles O Smith; Shannon G Loelius; Rachel A Berg; Xu Shi; Ryan M Burke; Sherry L Spinelli; Scott J Cameron; Thomas E Carey; Paul S Brookes; Robert E Gerszten; Maria Sabater-Lleal; Paul S de Vries; Jennifer E Huffman; Nicholas L Smith; Craig N Morrell; Charles J Lowenstein
Journal:  Nat Commun       Date:  2020-07-13       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.